Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced the US FDA has accepted Kura’s New Drug Application seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory AML with a nucleophosmin 1 (NPM1) mutation.